ILMN 📈 Illumina - Overview

Illumina, Inc. is a leading provider of genetic and genomic analysis solutions, operating globally with a presence in the United States, Singapore, the United Kingdom, and other international markets. The company's business is segmented into two main areas: Core Illumina and GRAIL. Core Illumina focuses on the development and commercialization of sequencing and array-based instruments, consumables, and services, while GRAIL is dedicated to the development of innovative cancer detection tests, including the multi-cancer early detection test, Galleri.

The company's product portfolio includes a range of sequencing and array-based instruments, such as the popular HiSeq and NovaSeq platforms, as well as consumables like reagents, flow cells, and library preparation kits. These products enable researchers and clinicians to perform whole-genome sequencing, targeted resequencing, and other types of genetic analysis. Illumina also offers a variety of kits and services, including whole-genome sequencing kits, genotyping services, and noninvasive prenatal testing. Additionally, the company is investing in the development of new solutions for cancer diagnosis, including blood-based detection of minimal residual disease and other post-diagnostic applications.

Illumina's customer base is diverse, comprising genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through a network of life-science distributors. With a strong focus on innovation and customer support, Illumina has established itself as a leader in the life sciences tools and services industry. Founded in 1998 and headquartered in San Diego, California, Illumina, Inc. is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol ILMN.

As a pioneer in the field of genomics, Illumina continues to push the boundaries of genetic and genomic analysis, enabling researchers and clinicians to gain a deeper understanding of the genetic basis of disease and develop new treatments and therapies. With its commitment to innovation, customer support, and collaboration, Illumina is well-positioned to drive growth and advancement in the life sciences industry. The company's website, https://www.illumina.com, provides more information on its products, services, and initiatives, as well as its mission to improve human health by unlocking the power of the genome.